Public health surveillance

USA Patient Registry Software Market Outlook to 2028, Featuring IQVIA, Optum (UnitedHealth Group), Phytel, Dacima Software, FIGmd, Syapse and Pharos Innovations - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 19, 2024
Oncology, Research, Software, University, Infectious Diseases, Education, Hospitals, Health Technology, Genetics, Health Insurance, Data Management, Science, Technology, Clinical Trials, Biotechnology, FDA, Insurance, Health, Professional Services, IOT (Internet of Things), Data Analytics, White House, Federal Government, Practice Management, Managed Care, Other Health, Public Policy, Government, Pharmaceutical, Other Science, Pancreatic disease, Consolidated, Patient, Conditional sentence, Optum, Health information management, Food and Drug Administration, Geography, NPF, RWE, Internet of things, Openclinica, DNA, Policy, Electronic health record, NIH, City, Privacy, CMS, Food, Organization, Prevalence, Federation, Internet, Cancer, Drug development, IQVIA, Evidence-based medicine, RDCRN, Type, Data science, Caregiver, Public health surveillance, Government agency, Registry, EHR, CDC, National Institutes of Health, Bangladesh Technical Education Board, Medicare, Collection, Medical device

The patient registry market in the US involves the collection, management & analysis of data related to patients with specific medical conditions & diseases.

Key Points: 
  • The patient registry market in the US involves the collection, management & analysis of data related to patients with specific medical conditions & diseases.
  • Patient registry software could facilitate data sharing and analysis among these entities, leading to increased adoption
    The patient registry software market in the USA is a part of the broader healthcare information technology sector.
  • Key players in the USA patient registry software market includes IQVIA, Dacima Software, OpenClinica, FIGmd, Dendrite Clinical Systems and various universities conducting medical clinical studies.
  • As technology & data science continue to evolve, the patient registry software market is likely to incorporate more advanced analytics techniques.

Terra is Now Generally Available on Microsoft Azure

Retrieved on: 
Wednesday, January 24, 2024
M42, VUMC, CICP, Privacy, Research, Environment, Health, GDPR, Broad Institute, Policy, Microsoft, Partnership, Biomedical Research, Global health, Genetics, Ecosystem, Data, Active Directory, Organization, MIT, Genomics, Harvard University, Public health surveillance, Microsoft Azure, Vanderbilt University Medical Center, EVP, Cryptocurrency

CAMBRIDGE, Mass., Jan. 24, 2024 /PRNewswire/ -- The Broad Institute of MIT and Harvard has made Terra generally available on Microsoft Azure. Terra is Broad's flagship biomedical data platform, co-developed by Broad, Microsoft, and Verily. The open-source platform is used by over 65,000 individuals globally for biomedical data analysis, secure data sharing, and cross-enterprise data science collaborations. Through Terra, researchers can gain access to genomics and other data modalities used for biomedical research, as well as run state-of-the-art workflows developed by Broad and wider bioinformatics community.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 24, 2024 /PRNewswire/ -- The Broad Institute of MIT and Harvard has made Terra generally available on Microsoft Azure.
  • Integration with Microsoft offerings: Researchers can seamlessly use the Azure ecosystem from within their Terra Workspace environment, such as connecting to Azure OpenAI Service and Azure Health Services.
  • "Terra on Microsoft Azure represents an important step toward accelerating scientific discovery through empowering responsible collaborative research across the global scientific community."
  • Now that Terra is on Azure, we are excited to align our use of Terra with our internal IT strategy."

Artificial Intelligence-Powered Drug Diversion Surveillance Now Part of Wolters Kluwer’s Sentri7 Suite

Retrieved on: 
Thursday, November 30, 2023
Software, Practice Management, Pharmaceutical, Health, Data Management, Hospitals, Health Technology, Technology, Public health surveillance, Safety, Antimicrobial stewardship, Pharmacist, Wolters Kluwer, Machine learning, Hospital, Drug diversion, AI, Nursing, Medical device, Pharmaceutical industry

To better equip healthcare facilities to address this growing threat to patient and staff safety, Wolters Kluwer Health is expanding its Sentri7® clinical surveillance suite to include the Sentri7 Drug Diversion solution, formerly Flowlytics® from Invistics.1

Key Points: 
  • To better equip healthcare facilities to address this growing threat to patient and staff safety, Wolters Kluwer Health is expanding its Sentri7® clinical surveillance suite to include the Sentri7 Drug Diversion solution, formerly Flowlytics® from Invistics.1
    Despite an increasing number of solutions available on the market to address drug diversion, healthcare executives’ confidence remains low.
  • The 2023 State of Drug Diversion Survey found only 40% of executives are very confident in the efficacy of their drug diversion detection programs.
  • Powered by AI and machine learning, the Sentri7 Drug Diversion solution aims to address these gaps in confidence with a proven track record of proactive drug diversion surveillance that minimizes the burden on hospital staff.
  • “Using the Sentri7 Drug Diversion solution, my team is in a better position to be proactive in our drug diversion surveillance, ultimately supporting heightened safety across our organization.

World Healthcare Data Research Report 2023: Market to Triple by 2030 - New Entrants and Incumbents are Leveraging RWD/RWE to Generate Valuable Insights

Retrieved on: 
Monday, November 13, 2023
Real-World Evidence, Drug development, Acquisition, Real, Organization, Health policy, Real world evidence, Electronic health record, RWD, Public health surveillance, Ecosystem, Health information management, Procurement, COVID-19, Flatiron, Evidence, RWE, Research report, Pharmaceutical industry, Sales, Research

The report provides valuable insights into the current and future state of the RWD/RWE market.

Key Points: 
  • The report provides valuable insights into the current and future state of the RWD/RWE market.
  • These trends are leading to a rapidly growing market, which this report forecasts will experience an average 14.6% CAGR through 2030, roughly tripling today's addressable market from $4.6B to $13.6B USD.
  • The research is relevant to any healthcare stakeholder looking to leverage real-world data for evidence-based decision making.
  • The mass digitization of healthcare records over the past decade has led to an explosion of new, highly-valued clinical data assets.

Laboratory Testing and PCR Technology Lead the India Infectious Disease Diagnostics Market, Transforming Disease Detection and Management - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 8, 2023
Health, Infectious Diseases, Pathogen, Laboratory, Research, Public health surveillance, RPA, Molecular biology, Infection, Parasitism, Biomarker, Contact tracing, Research and development, CRISPR, PCR, Disease, Sputum, Fungus, Virulence, LAMP, Whole genome sequencing, Artificial intelligence, Vaccination, Urine, NGS, Diagnosis, COVID-19, Medicine, WGS, Blood, Microscopy, Public, Gene expression, DNA, Vaccine, Pharmaceutical industry, Epidemiology

The India emerging infectious disease diagnostics market is set for substantial growth over the forecast period from 2023 to 2033.

Key Points: 
  • The India emerging infectious disease diagnostics market is set for substantial growth over the forecast period from 2023 to 2033.
  • The India emerging infectious disease diagnostics market is currently in an emerging phase.
  • The India emerging infectious disease diagnostics market plays a pivotal role in modern biotechnology, clinical diagnostics, and pathogen research.
  • The India emerging infectious disease diagnostics market is segmented into key categories:
    In FY2022, laboratory testing was the dominant application segment in the India emerging infectious disease diagnostics market.

Truveta and Mathematica partner to advance public health and health equity with real-world data

Retrieved on: 
Thursday, September 21, 2023
Partnership, Public, Policy, Health equity, Research, Maternal health, Health policy, Public sector, EHR, Action, Health, MPH, Public health surveillance, Nursing, MD, Wolfram Mathematica

BELLEVUE, Wash. and PRINCETON, New Jersey, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Truveta, a leading EHR data and analytics company, and Mathematica, a policy research and data analytics consultancy, today announced a partnership to advance medical research in the areas of public health surveillance, health equity, and maternal health.

Key Points: 
  • BELLEVUE, Wash. and PRINCETON, New Jersey, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Truveta, a leading EHR data and analytics company, and Mathematica, a policy research and data analytics consultancy, today announced a partnership to advance medical research in the areas of public health surveillance, health equity, and maternal health.
  • By engaging with leading public sector agencies and philanthropies focused on these areas, Truveta and Mathematica will improve patient care and outcomes – including health equity – across the United States.
  • With this partnership with Mathematica, we will be able to advance medical research in many ways, informing important public health conversations, advancing health equity, and addressing maternal health,” said Ryan Ahern, MD, MPH, chief medical officer and co-founder, Truveta.
  • “With the timeliness and completeness of Truveta Data, Mathematica can now partner with critical public sector agencies and philanthropies to advance patient-centered outcomes research and address some of the most important issues in healthcare today.”

Gravity Diagnostics Expands Testing Services to Include Xylazine Detection: A Crucial Advancement in Ensuring Public Safety

Retrieved on: 
Wednesday, September 20, 2023
Central nervous system, Diagnosis, Prevalence, Education, Public, Commitment, Heroin, CDC, Harm reduction, Death, Toxicology, Prohibition, Drug, Public health surveillance, Patient safety, Health, Fentanyl, Safety, Pharmaceutical industry, Medical device, Dietary supplement, Online shopping, Xylazine

By including Xylazine in their testing menu, Gravity Diagnostics aims to address the growing concerns surrounding its use and provide critical information to healthcare providers.

Key Points: 
  • By including Xylazine in their testing menu, Gravity Diagnostics aims to address the growing concerns surrounding its use and provide critical information to healthcare providers.
  • **Benefits of Choosing Gravity Diagnostics for Xylazine Testing: **
    **Accurate and Reliable Results**: Gravity Diagnostics is renowned for its state-of-the-art testing technologies and highly trained staff, ensuring the utmost accuracy and reliability in Xylazine detection.
  • **Commitment to Safety**: Gravity Diagnostics' mission is to improve public safety and health, and by offering Xylazine testing, they are taking a proactive step towards achieving this goal.
  • For more information about their Xylazine testing services or to inquire about their comprehensive toxicology solutions, please contact them at [email protected]

America's DataHub Consortium announces selection of Clinovations Government + Health for National Vital Statistics System Modernization Project

Retrieved on: 
Wednesday, September 20, 2023
National Center for Science and Engineering Statistics, Science, Metadata, NSDS, Engineering, Statistics, National Science Foundation, Blog, Privacy, Confidentiality, Data access, Government, Public sector, Organization, NVSS, Quality assurance, Engineering statistics, ADC, Public health surveillance, Nursing

WASHINGTON, Sept. 20, 2023 /PRNewswire/ -- America's DataHub Consortium (ADC) partnered with National Center for Science and Engineering Statistics within the National Science Foundation to release a request for solutions that highlighted new opportunities for the use of interoperable health data to support public health surveillance: National Vital Statistics System Modernization — New Opportunities for Interoperable Data .

Key Points: 
  • WASHINGTON, Sept. 20, 2023 /PRNewswire/ -- America's DataHub Consortium (ADC) partnered with National Center for Science and Engineering Statistics within the National Science Foundation to release a request for solutions that highlighted new opportunities for the use of interoperable health data to support public health surveillance: National Vital Statistics System Modernization — New Opportunities for Interoperable Data .
  • After a competitive evaluation, the selection committee chose Clinovations Government + Health for award.
  • It is the first "non-traditional" organization to be selected for an ADC project.
  • Their expertise lies in offering innovative solutions at the intersection of healthcare and technology, a key factor in their approach to this project.

From HITECH to the COVID-19 PHE: These Real-World Data Technologies are Helping Define Evidence-Based Care

Retrieved on: 
Wednesday, August 30, 2023
Real-World Evidence, Cosmos, Komodo, Real, Research report, Drug development, Procurement, Thermo Fisher Scientific, Real world evidence, COVID-19, RWD, Electronic health record, Health policy, Organization, Evidence, Aetion, Acquisition, RWE, Health Information Technology for Economic and Clinical Health Act, Carev Dvor, Ecosystem, Public health surveillance, Health information management, Pharmaceutical industry, IQVIA, Tempus, Research

'Real-world data' (RWD) has been used in a variety of research purposes to develop 'real-world evidence' (RWE) for decades, but never to the extent that is occurring today.

Key Points: 
  • 'Real-world data' (RWD) has been used in a variety of research purposes to develop 'real-world evidence' (RWE) for decades, but never to the extent that is occurring today.
  • However, nearly 80% of healthcare data is still in unstructured formats, necessitating specialized solutions that can help process this data so it can be applied effectively.
  • "By working together, they can overcome barriers such as data fragmentation, data quality concerns, and regulatory uncertainties.
  • The research is relevant to any healthcare stakeholder looking to leverage real-world data for evidence-based decision making.

Wolters Kluwer awarded highest client satisfaction award from Black Book Research

Retrieved on: 
Wednesday, July 26, 2023
Software, Practice Management, Health, Data Management, Hospitals, Health Technology, Technology, Security, Learning, Wolters Kluwer, Research, USP, Electronic health record, Sepsis, Houston, Public health surveillance, Student, Hospital, Patient, Patient safety, Internationalized domain name, Black Book, Nursing

Wolters Kluwer Health today announced that the Sentri7® clinical surveillance and Simplifi+® pharmacy compliance teams received a 2023 Black Book award for highest client satisfaction.

Key Points: 
  • Wolters Kluwer Health today announced that the Sentri7® clinical surveillance and Simplifi+® pharmacy compliance teams received a 2023 Black Book award for highest client satisfaction.
  • Wolters Kluwer was ranked among the highest-scoring hospital IT and support suppliers in the Black Book client experience polls.
  • “Black Book is committed to recognizing top performers like Wolters Kluwer Health; their Clinical Surveillance and Compliance group stands out among others in the healthcare technology industry's most robust client satisfaction database," said Doug Brown, President of Black Book Research.
  • The division of Wolters Kluwer supports clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions.